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Background: Glioblastoma multiforme (GBM) frequently recurs at the same location after radiotherapy. Further
dose escalation using conventional methods is limited by normal tissue tolerance. 4π non-coplanar radiotherapy
has recently emerged as a new potential method to deliver highly conformal radiation dose using the C-arm linacs.
We aim to study the feasibility of very substantial GBM dose escalation while maintaining normal tissue tolerance
using 4π.
Methods: 11 GBM patients previously treated with volumetric modulated arc therapy (VMAT/RapidArc) on the
NovalisTx™ platform to a prescription dose of either 59.4 Gy or 60 Gy were included. All patients were replanned
with 30 non-coplanar beams using a 4π radiotherapy platform, which inverse optimizes both beam angles and
fluence maps. Four different prescriptions were used including original prescription dose and PTV (4πPTVPD), 100 Gy
to the PTV and GTV (4πPTV100Gy), 100 Gy to the GTV only while maintaining prescription dose to the rest of the PTV
(4πGTV100Gy), and a 5 mm margin expansion plan (4πPTVPD+5mm). OARs included in the study are the normal brain
(brain – PTV), brainstem, chiasm, spinal cord, eyes, lenses, optical nerves, and cochleae.
Results: The 4π plans resulted in superior dose gradient indices, as indicated by >20% reduction in the R50,
compared to the clinical plans. Among all of the 4π cases, when compared to the clinical plans, the maximum and
mean doses were significantly reduced (p < 0.05) by a range of 47.01-98.82% and 51.87-99.47%, respectively, or
unchanged (p > 0.05) for all of the non-brain OARs. Both the 4πPTVPD and 4π GTV100GYplans reduced the mean
normal brain mean doses.
Conclusions: 4π non-coplanar radiotherapy substantially increases the dose gradient outside of the PTV and better
spares critical organs. Dose escalation to 100 Gy to the GTV or additional margin expansion while meeting clinical
critical organ dose constraints is feasible. 100 Gy to the PTV result in higher normal brain doses but may be tolerated
when delivered in proportionally increased treatment fractions. Therefore, 4π non-coplanar radiotherapy on C-arm
gantry may provide an accessible tool to improve the outcome of GBM radiotherapy through extreme dose escalation.Introduction
Glioblastoma multiforme (GBM) is a devastating disease
with a dismal survival rate. Even with aggressive surgical
and chemoradiation, the average survival period is 12–
14 months after diagnosis [1]. Although radiotherapy
has been shown to delay recurrence and prolong patient
survival, GBM is remarkably resistant to treatment and
has a high recurrence rate that contributes to patient
mortality. The recurrence overwhelmingly occurs in or
near the high-dose radiation field and original tumor site* Correspondence: ksheng@mednet.ucla.edu
Department of Radiation Oncology, University of California, Los Angeles,
200 Medical Plaza Way, Suite B265, Los Angeles, USA
© 2014 Nguyen et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[2]. The biology behind the radiation resistance is not
well understood but the pattern of recurrence suggests
that there may be surviving tumor cells within or near
the high dose area. This observation has motivated dose
escalation studies. An increased survival period with
dose escalation up to 60 Gy has been observed based on
a non-randomized clinical trial [3], although this im-
provement was achieved without advancing the local
control rates.
Dose escalation studies utilizing three-dimensional
conformal radiotherapy showed that, even with dose es-
calation to 70 Gy and 80 Gy, the recurrences from
highly conformal treatments are still predominantly locall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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local control, instead, worsened the patient survival period
possibly due to the increased treatment related toxicity
[4,5]. Studies that have attempted other methods to treat
GBM, such as a phase II trial utilizing weekly stereotactic
radiotherapy boost [6] and a phase I trial of hypofractio-
nated IMRT with temozolomide chemotherapy [7], have
also found predominantly local recurrence and no survival
benefit.
Further dose escalation using external X-ray beams
alone was deemed infeasible due to normal tissue dose
constraints. To increase the tumor dose, a phase II pro-
spective trial using combined proton and photon therapy
to deliver 90 Gy showed improved central tumor con-
trol, and increased median survival period to 20 months
[8]. Although the total radiation dose is the same as the
photon trial, the treatment was delivered in a bis in die
(b.i.d. or twice a day) fashion, resulting in a substantially
greater biological equivalent dose. Alternatively, a Northern
California Oncology Group (NCOG) trial utilized brachy-
therapy to boost the tumor dose [9,10]. After being treated
to a median prescription dose of 59.5 Gy via external
beam radiation therapy, patients received a boost dose
to the GTV from an 125I (10–40 mCi) with a dose rate
of 40–60 cGy/hr to a median boost dose of 50.88 Gy
within 5–6 days, totaling to approximately 110 Gy.
The results from this non-randomized clinical trial
showed that the dose escalated GBM patients achieved
an improved 1 and 2 year survival rate of 87% and 57%
when compared to the control group receiving external
beam radiation only of 40% and 12.5%, respectively. In
a recurrent GBM trial using the same regimen, 10% (3)
patients achieved a 5 year disease-free survival al-
though the overall pattern of recurrence after radio-
therapy and chemotherapy remained predominantly local
[11]. While this treatment regimen is toxic and often re-











1 262.49 379.9 66.7 1724.3 149
2 265.78 400.2 71.6 1406.6 117
3 231.97 368.2 56.7 1163.8 949
4 252.33 363.5 67.9 1539.2 132
5 272.41 416.3 101.8 1356.1 112
6 426.32 609.5 132.2 1418.1 104
7 429.82 548.5 124.6 1241.9 890
8 377.77 555.0 120.0 1473.9 110
9 402.40 567.6 144.5 1657.3 130
10 196.42 342.2 39.8 1542.5 135
11 463.52 699.0 143.5 1398.6 100necrosis induced by the aggressive treatment, it indicated
the potential for substantially improving GBM patient
treatment outcomes with very aggressive dose escalation
to 100 Gy or greater.
Brain brachytherapy implant is associated with signifi-
cant risk and the procedure itself may have contributed to
the severe side effects. The complexities involved in the
brachytherapy procedures and resulting patient manage-
ment have prevented it from being widely and sustainably
applied. At the times of the aforementioned clinical trials,
external beam alone was deemed insufficiently conformal
to deliver such high doses due to normal tissue dose con-
straints. Brain necrosis is the dominant presentation of
treatment related toxicity from dose escalation studies be-
yond 60 Gy. Therefore, reducing the high dose spillage by
increasing dose distribution compactness is critical to the
success of dose escalation.
With the recent advent of highly conformal non-
coplanar intensity modulated 4π therapy, markedly im-
proved radiation dose conformity has been demonstrated
[12-14]. Specifically, a significant reduction of the high
dose spillage has been observed. This dosimetric improve-
ment may afford GBM dose escalation to 100 Gy or greater
using external beam only with the hope of achieving a sur-
vival benefit, without significantly increasing toxicity.
Patients & methods
11 GBM Patients, 8 male and 3 female, were included in
the study. The maximum, minimum, and median ages
were 66 years, 26 years, and 49 years, respectively. De-
tailed patient information of 11 GBM Patients included
in the study is shown in Table 1. The gross tumor vol-
ume (GTV) was delineated on a contrast enhanced mag-
netic resonance imaging (MRI) manually fused to the
CT simulation scan. The GTV was defined as the gross
disease enhancing on the T1-weighted MRI images plus







2.0 60 2 non-cop L frontal
1.2 60 2 non-cop L temporal
.6 59.4 3 non-cop R temporal
1.2 59.4 3 non-cop L temporal
3.9 59.4 3 non-cop L frontal
1.6 59.4 3 non-cop R parietal
.7 59.4 2 coplanar L frontal
2.0 59.4 2 coplanar L frontal
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fined as the GTV + 2 cm expansion with anatomical
considerations. Lastly, the planning target volume (PTV)
was defined as the CTV + 0.5 cm expansion. Patients
were treated to a prescription dose of either 59.4 Gy or
60 Gy to 95% of the PTV. For all patients, highly con-
formal volumetric modulated arc therapy (VMAT) plans
were designed using Eclipse (Varian Medical Systems,
Palo Alto, California) with 2 to 4 coplanar or non-coplanar
arcs as necessary to achieve optimal critical structure spar-
ing. Final dose calculation was performed using the analyt-
ical anisotropic algorithm (AAA) planning algorithm. This
planning method was shown equivalent or superior to
static beam IMRT, particularly with the additional partial
arcs [15]. The organs-at-risk (OARs) typically involve the
optical apparatus and brainstem, which are subject to max-
imal dose constraints and the brain, which has tolerances
that depend on both the maximal and volume dose. OAR
dose tolerances were defined according to RTOG protocol
0825 with the following maximum point dose con-
straints: chiasm <56 Gy, lens <7 Gy, brainstem <60 Gy,
optic nerve <55 Gy and cochlea <45 Gy. It has been re-
ported that in conventionally fractionated radiotherapy,
a maximal dose of 72 Gy (range 60 – 84Gy) results in a
5% risk of symptomatic radiation necrosis at 5 years
and the risk increases to 10% with 90 Gy [16]. In this
study, normal brain doses greater than 60 Gy as well as
the mean brain doses were constrained. In addition, it
had been observed in brain SRS studies that there is a
rapid rise of brain necrosis when the volume of brain
receiving 12 Gy or greater (V12) is more than 5–
10 cm3 [17]. This single fraction dose is biologically
equivalent to 36 Gy delivered in 2 Gy daily fractions.
Therefore, additional DVH points were used to panelize
normal brain receiving 30–36 Gy in the VMAT plans.
Treatment was planned for a NovalisTx system equipped
with a 2.5 mm leaf-width MLC.
4π non-coplanar radiotherapy was implemented fol-
lowing previous publications [12-14]. Briefly, 4π radio-
therapy is a non-coplanar planning platform established
on existing C-arm gantry linacs. The 4π optimization
method starts with a candidate pool of 1162 beams evenly
distributed throughout the 4π solid angle space with 6° of
separation between adjacent beams. Beams causing colli-
sion between the gantry and couch or patient are excluded
using a collision map based on the 3D surface image of
the machine and a human subject. The remaining pool
of candidate beams subdivided into 5 × 5 mm2 beam-
lets, are calculated utilizing convolution/superposition
of Monte Carlo calculated 6 MV poly-energetic kernels.
A column generation algorithm [18] is used to itera-
tively select and optimize beam fluence until the
desired number of beams is reached. In this case, 30
non-coplanar beams were utilized for each patient.Dose constraints similar to those of VMAT plans were
applied.
The dose calculation resolution was 2.5 mm on both
the clinical and 4π plans, which were then exported to a
Matlab program (Computational Environment for Radi-
ation Research CERR, Washington University) for dosi-
metric comparison.
Quantitative analysis was used to compare the mean
and maximum OARs and PTV doses, as well as R50, a
measurement of high dose spillage or dose gradient out-
side the PTV, which is defined as the ratio between 50%
isodose volume and the PTV. V30 and V36, markers for
potential brain necrosis, were assessed. To test how dose
escalation affects the low dose region, V5, V10, and V20
were also evaluated. “Vx” is defined as the volume that
has “x Gy” of dose or higher.
The 4π plans with the original prescription doses
(4πPTVPD) were compared to the clinical plans. To test
the hypothesis of minimal risk dose escalation, 3 differ-
ent 4π planning schemes, including dose escalation or
margin increase, were investigated.
As suggested by the literature, dose escalation from
60 Gy to 100 Gy or greater is needed to significantly im-
prove GBM patient survival. In the first two schemes,
we prescribed 100 Gy to cover 95% of the PTV and
GTV, named 4πPTV100Gy and 4πGTV100Gy, respectively.
In the 4πGTV100Gy scheme, the remaining PTV was
covered by the prescription dose. Literature also suggests
that in addition to the high central recurrence rates,
GBM is also likely to recur at the field margin. In the
last scheme, the original PTV was further expanded by
5 mm while maintaining the original prescription doses
(4πPTVPD+5mm). The expanded margins were adjusted
to not extend beyond the outer skull and to avoid crit-
ical structures, unless the original PTV already encom-
passed part of the structure. Doses to the normal brain,
which excluded the PTV contour, were evaluated. For
the 4πPTVPD+5mm plan, the normal brain was still de-
fined to exclude the original PTV.
The Wilcoxon signed-rank test was utilized to compare
the 4π plans against the clinical plan. Evaluated OARs in-
cluded the brain, brainstem, chiasm, spinal cord, eyes,
lenses, optical nerves, and cochleae.
Results
Figure 1 shows the beam entrance patterns of a typical
non-coplanar 4π plan and the corresponding VMAT plan
utilizing two partial non-coplanar arcs.
All of the 4π plans exhibited a decrease in maximum and
mean doses for the OARs exclusive of the brain. Table 2
lists the average percent maximum and mean OARs dose
reductions for 4π compared to the clinical plans. The
4πPTVPD plans significantly reduced (p < =0.003) the ma-
ximum and mean brainstem dose by 47% and 61%,
Figure 1 Typical beam patterns of 4π beams vs. VMAT beams.
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non-brain OARs by a range of 74-98% and 90-99%, respect-
ively. The 4πPTV100Gy plans produced unchanged (p >
0.05) maximum and mean doses in the brainstem, and a




Average Max Dose Reduction (%)
% p-value % p-
Brainstem 47.01 0.003 7.18 0.8
Chiasm 84.73 <0.001 72.12 <0
Spinal Cord 73.98 0.007 39.79 0.2
Left Eye 83.89 <0.001 69.03 <0
Right Eye 88.01 <0.001 76.16 <0
Left Lens 98.43 <0.001 94.96 <0
Right Lens 97.74 <0.001 93.88 <0
L Opt Nrv 87.12 <0.001 74.31 <0
R Opt Nrv 89.93 <0.001 80.42 <0
L Cochlea 82.45 <0.001 64.87 0.0
R Cochlea 93.58 <0.001 85.19 0.0
Average Mean Dose Reduction (%)
Brainstem 60.96 0.002 38.08 0.0
Chiasm 95.30 <0.001 88.88 <0
Spinal Cord 92.43 <0.001 80.07 <0
Left Eye 94.61 <0.001 85.66 <0
Right Eye 95.94 <0.001 87.95 <0
Left Lens 99.23 <0.001 97.11 <0
Right Lens 99.10 <0.001 96.56 <0
L Opt Nrv 95.98 <0.001 87.66 <0
R Opt Nrv 97.48 <0.001 94.08 <0
L Cochlea 90.34 <0.001 78.41 0.0
R Cochlea 96.83 <0.001 92.81 0.0mean doses to other OARs, exclusive of the brain, in the
range of 65-95% and 78-97%, respectively, except for an in-
significant change (p > 0.05) in the spinal cord dose when
compared to the clinical plans. The 4πGTV100Gy study did
not change the brainstem maximal doses (p > 0.05), butof the OARs except the normal brain
4πGTV100Gy 4πPTVPD+5mm
value % p-value % p-value
98 27.65 0.123 30.66 0.003
.001 86.74 <0.001 77.06 <0.001
40 84.22 0.006 51.94 0.064
.001 87.03 <0.001 66.86 <0.001
.001 88.11 <0.001 84.12 <0.001
.001 98.63 <0.001 97.53 <0.001
.001 98.82 <0.001 97.59 <0.001
.001 88.45 0.002 72.44 <0.001
.001 91.33 0.005 75.72 <0.001
05 84.15 0.003 44.94 0.067
01 93.10 <0.001 77.97 0.007
67 57.77 <0.001 51.87 0.002
.001 96.23 <0.001 92.27 <0.001
.001 98.08 <0.001 71.51 0.014
.001 96.49 <0.001 89.78 <0.001
.001 96.69 <0.001 94.24 <0.001
.001 99.44 <0.001 98.56 <0.001
.001 99.47 <0.001 98.72 <0.001
.001 96.96 <0.001 88.46 <0.001
.001 98.42 <0.001 93.09 <0.001
02 85.92 0.002 60.16 0.037
03 97.79 <0.001 90.83 0.002
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remaining OARs, exclusive of the brain, showed a signifi-
cant decrease (p < 0.006) in the maximum and mean doses
by a range of 84-99% and 86-99%, respectively. The
4πPTVPD+5mm plan significantly reduced the (p < = 0.003)
maximum and mean doses for the brainstem by 31% and
52%, respectively, and reduced (p < 0.04) the maximum and
mean doses to other OAR, exclusive of the brain, by a
range of 67-98% and 60-99%, respectively, except for the
unchanged (p > 0.05) maximum doses in the spinal cord
and left cochlea, when compared to the clinical plans.
Figure 2 compares the normal brain maximum dose,
mean dose, V30, and V36 between the clinical plan and
the 4π plans. The 4πPTVPD plans significantly reduced
(p < 0.001) the mean brain dose from 21.94 Gy to 16.56 Gy
and slightly increased the maximum normal brain doses
(p < 0.001) from 63.24 to 64.88 Gy. The maximum normal
brain doses increased (p < 0.001) in the 4πPTV100Gy and
4πGTV100Gy plans to 108.71 Gy and 98.51 Gy respectively.
The 4πPTV100Gy plans also significantly increased (p <
0.001) the mean brain dose to 27.60 Gy (26%), while the
4πGTV100Gy significantly decreased (p < 0.001) the mean
brain dose to 17.61 Gy (20%). For the 4πPTVPD+5mm plans,
the maximum brain dose slightly increased (p < 0.001)
from 63.24 Gy to 64.94 Gy, and the brain mean dose was
statistically unchanged (p > 0.05).
Brain dose comparison for individual patients is shown
in Figure 2. V36 and V30, surrogates for potential brain
necrosis, were significantly decreased (p < 0.001), for the
4πPTVPD and the 4πGTV100Gy plans, statistically un-
changed for the 4πPTVPD+5mm plan, and significantlyFigure 2 Individual patient dosimetry comparisons between clinical Vincreased (p < 0.001) for the 4πPTV100Gy plan. In the
4πPTVPD and 4πGTV100Gy plans, the brain V36 signifi-
cantly decreased (p < 0.001) by 94.77 cm3, 90.92 cm3,
respectively. Similarly, the brain V30 decreased by
144.92 cm3, 127.63 cm3 for the same plans. The brain V36
and V30 of the 4πPTV100Gy plan significantly increased
(p < 0.001) by 108.62 cm3 and 91.81 cm3, respectively. V5,
V10, and V20 were also significantly decreased (p < 0.01)
in the the 4πPTVPD and 4πGTV100Gy plans, and statisti-
cally unchanged (p > 0.05) in the 4πPTVPD+5mm and
4πPTV100Gy plan. A comparison of the average volumes
plotted against the various “Vx” are shown in Figure 3.
Figure 4 shows a dose colorwash superimposed on
the planning CT for a typical case. The dose fall-off
outside the PTV is steeper in the 4π cases. R50 was sig-
nificantly lowered from 2.52 in the clinical plans to 1.97
(4πPTVPD), 2.00 (4πPTV100Gy), 2.10 (4πGTV100Gy), and
1.75 (4πPTVPD+5mm) respectively. The DVHs shown in
Figure 5 compare the PTV and the brain doses. With
the exception of the 4πPTV100Gy plans, the 4π plans re-
duced dose to the brain and brainstem while maintain-
ing superior doses to the tumor. 4π plans resulted in
essentially equivalent or slightly superior PTV coverage
compared to the clinical plans.
Discussion
GBM tumors are nested within the normal brain tissue
and are often proximal to other serial critical organs.
Currently established dose of approximately 60 Gy to
the GBM tumor has shown survival benefit compared to



























Figure 3 Comparison of volumes between the clinical and 4π plans.
Nguyen et al. Radiation Oncology 2014, 9:239 Page 6 of 8
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escalation studies to over 100 Gy or therapy using boron
neutron capture therapy [19] with high radiobiological
equivalent dose show that very aggressive dose escal-
ation could provide meaningful improvement in tumor
response. However, attempting dose escalation without
drastically improving the dose compactness will result in
a greater severe toxicity risk long before reaching a tumor
doses that can significantly delay GBM recurrence, let
alone the dose needed for permanent local tumor control.
Previous dose escalation studies utilizing 3D conformal ra-
diation therapy have shown worse patient survival [4,5]
largely due to the lack of dose conformity around the tar-
get. Compared to 3D conformal radiation therapy used in
the aforementioned clinical trials, intensity modulated ra-
diation therapy (IMRT) better conforms radiation doses
to the target. However, intensity modulation does not fun-
damentally change the “compactness” of dose distribution
[20], which has been commonly defined using the ratio ofFigure 4 Dose wash of the clinical case and the various 4π plans for athe 50% isodose volume to the PTV volume. Previous
dose escalation studies to beyond 100 Gy BED had to
utilize proton therapy or brachytherapy, severely limiting
their applicability [8-10]. Brachytherapy particularly in-
creases the bleeding and infection risk, making it a less ap-
pealing option for many clinics.
It has been previously shown that 4π radiotherapy will
provide improved dose compactness compared to copla-
nar arc and manually selected non-coplanar IMRT ap-
proaches [12]. Selecting and optimizing beams in the
vast non-coplanar solution space is an enormously com-
plex problem that has become manageable using innova-
tive optimization algorithms such as the column generation
approach. Using our 4π research-planning platform, we
showed that GTV dose escalation to 100 Gy is achiev-
able while maintaining lower mean and maximum OAR
doses. Use of this technique may result in delayed or
reduced central recurrences. To effectively reduce mar-
ginal recurrences, dose escalation to the entire PTV orsingle patient.



























































Figure 5 Cumulative dose volume histogram comparisons for a
typical patient. (a) Dose volume histogram comparing the clinical
plan to the 4πPTVPD plan and the 4πPTVPD+5mm plan. (b) Dose
volume histogram comparing the clinical plan to the 4πPTV100Gy
plan and the 4πGTV100Gy plan.
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itional 5 mm can be added without increasing normal
tissue doses. The 4πPTV100Gy plans unavoidably in-
creased the brain maximum and mean doses and V30
and V36. It remains to be seen whether these doses
could be safely delivered, but if a consistent fraction-
ation is employed, the greater doses will be delivered
using more fractions. For example, delivering the
100 Gy in 50 fractions instead of the 30–33 fractions
required for the original plan, the biological equivalent
dose to normal brain tissue would be decreased from
between 211.11 and 201.01 Gy to 166.67 Gy.
Like all dosimetry comparison studies, there is often
question whether the best possible plan has been achieved
in either planning platform. While subjective biases can-
not be completely ruled out, the large differences in nor-
mal organ doses exceed typical variation in plan quality
from the same planning platform. Furthermore, R50 as a
measurement of dose compactness has been a highly re-
producible parameter that is not substantially affected by
the selection of penalties and constraints in optimization.
Therefore, the observed significant difference in R50 is
unlikely due to operators.Therefore, with the advent of 4π radiotherapy, it is now
feasible to employ markedly improved dose conformity
and compactness for meaningful GBM dose escalation
using external beam X-rays alone. 4π radiotherapy using
C-arm gantries is less invasive than brachytherapy and
more accessible than proton beams. There are practical
hurdles to deliver these plans, namely collision avoidance
and delivery efficiency. While collision angles can be ex-
cluded based on the patient specific surface measure-
ments, the delivery time will include the greater time
required to move the couch and gantry between the nu-
merous beams. Based on our experience delivering 4π test
plans on a TrueBeam machine (Varian, Palo Alto) using
automated sequencing, the total time for the machine to
travel between 30 non-coplanar beams was less than
200 seconds and total treatment time from the first to the
last beam less than 15 minutes. The couch rotation in a
typical 4π treatment involves many small steps totaling
less than 180°. Such magnitudes of couch kicks are rou-
tinely used in linac based brain stereotactic radiosurgery
and appear to be well tolerated. Overcoming these prac-
tical hurdles and integrating 4π into a clinical delivery flow
will allow for equivalent or better patient survival than the
previous dose escalation studies.
Conclusion
The significantly improved dose coverage and high dose
conformity of 4π radiotherapy made it possible to escalate
the GBM prescription doses from 60 Gy to 100 Gy or to
increase the PTV margins while meeting clinical critical
organ dose constraints. For GBM, this 4π non-coplanar
radiotherapy modality may subsequently improve the GBM
treatment outcome.
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